Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Post by Jesus4Prezon Mar 29, 2021 6:00pm
497 Views
Post# 32901161

Motivation

MotivationHey Guys/Gals:

Just to speak briefly to the idea that DM is not incentivized to advance this company.  I may be wrong on exact numbers, but I believe that with shares, options, RSU's combined Don has around 7 million shares under his belt.

If they can grow this company so that his holdings gain a value of $30-40/unit, you can do the math.  What if they managed not to sell this company, and apabetalone went to market, eventually under multiple indications.  Can you imagine a scenario where the share price could go to $100?  If so, do the math, is Don incentivized?

If Don was 45 years old, he might be thinking about keeping BP away for the triple digit share price.  This type of thing does occur in the biotech world.  It just requires success and time.  We are told time is money, but more importantly as you get older in this world, time is time, kind of like land 'they aren't making more of it'.

I would merely guess that Don would love to sell this company, enjoy the rest of his time in this world, with more than enough money, and generate future oyalties for those he loves.

And so I am guessing that negotiations are ongoing, but somewhat contingent on the possiblity of a Covid home-run.  After clarity on that topic emerges, as it relates to apabetalone, then I suspect its decision time for everyone involved.

Hang in there people if you agree.

J4P
<< Previous
Bullboard Posts
Next >>